Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Gastrointestinal Medicine
Volume 2015, Article ID 132030, 6 pages
http://dx.doi.org/10.1155/2015/132030
Case Report

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?

1Department of Gastroenterology, Otaru General Hospital, 1-2-1 Wakamatu, Otaru 047-8550, Japan
2Department of Surgery, Otaru General Hospital, 1-2-1 Wakamatu, Otaru 047-8550, Japan
3Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan
4Department of Laboratory Medicine, Otaru General Hospital, 1-2-1 Wakamatu, Otaru 047-8550, Japan

Received 22 October 2014; Accepted 10 March 2015

Academic Editor: Olga I. Giouleme

Copyright © 2015 Yu Ishimine et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Van Cutsem, V. M. Moiseyenko, S. Tjulandin et al., “Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group,” Journal of Clinical Oncology, vol. 24, no. 31, pp. 4991–4997, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. W. Koizumi, H. Narahara, T. Hara et al., “S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial,” The Lancet Oncology, vol. 9, no. 3, pp. 215–221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Cunningham, N. Starling, S. Rao et al., “Capecitabine and oxaliplatin for advanced esophagogastric cancer,” The New England Journal of Medicine, vol. 358, no. 1, pp. 36–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. Y.-J. Bang, E. van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. D. J. Slamon, W. Godolphin, L. A. Jones et al., “Studies of the HER-2/neuproto-oncogene in human breast and ovarian cancer,” Science, vol. 244, no. 4905, pp. 707–712, 1989. View at Publisher · View at Google Scholar · View at Scopus
  6. D. M. Reese and D. J. Slamon, “HER-2/neu signal transduction in human breast and ovarian cancer,” Stem Cells, vol. 15, no. 1, pp. 1–8, 1997. View at Google Scholar · View at Scopus
  7. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Gianni, U. Dafni, R. D. Gelber et al., “Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial,” The Lancet Oncology, vol. 12, no. 3, pp. 236–244, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Gianni, W. Eiermann, V. Semiglazov et al., “Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort,” The Lancet Oncology, vol. 15, no. 6, pp. 640–647, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Liu, H. Deng, W. Jia et al., “Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment,” Journal of Cancer Research and Clinical Oncology, vol. 138, no. 5, pp. 837–842, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Nakamura, N. Yamamoto, Y. Onai, Y. Watanabe, H. Kawana, and M. Miyazaki, “Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients,” Breast Cancer, vol. 20, no. 4, pp. 336–341, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. M. V. Dieci, E. Barbieri, F. Piacentini et al., “Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis,” Annals of Oncology, vol. 24, no. 1, Article ID mds248, pp. 101–108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. E. M. de Dueñas, A. L. Hernández, Á. G. Zotano et al., “Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study,” Breast Cancer Research and Treatment, vol. 143, no. 3, pp. 507–515, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Xiao, Y. Gong, E. Y. Han, A. M. Gonzalez-Angulo, and N. Sneige, “Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment,” Annals of Oncology, vol. 22, no. 7, pp. 1547–1553, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Shet, A. Agrawal, R. Chinoy, R. Havaldar, V. Parmar, and R. Badwe, “Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy—implications for a pathologist,” The Breast Journal, vol. 13, no. 5, pp. 457–464, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Kasami, T. Uematsu, M. Honda et al., “Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy,” Breast, vol. 17, no. 5, pp. 523–527, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Hirata, C. Shimizu, K. Yonemori et al., “Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer,” British Journal of Cancer, vol. 101, no. 9, pp. 1529–1536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. E. A. Mittendorf, Y. Wu, M. Scaltriti et al., “Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes,” Clinical Cancer Research, vol. 15, no. 23, pp. 7381–7388, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Guarneri, M. V. Dieci, E. Barbieri et al., “Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients,” Annals of Oncology, vol. 24, no. 12, pp. 2990–2994, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Niikura, J. Liu, N. Hayashi et al., “Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors,” Journal of Clinical Oncology, vol. 30, no. 6, pp. 593–599, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Pectasides, A. Gaglia, P. Arapantoni-Dadioti et al., “HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy,” Anticancer Research, vol. 26, no. 1, pp. 647–654, 2006. View at Google Scholar · View at Scopus
  22. M. Hofmann, O. Stoss, D. Shi et al., “Assessment of a HER2 scoring system for gastric cancer: results from a validation study,” Histopathology, vol. 52, no. 7, pp. 797–805, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Rüschoff, W. Hanna, M. Bilous et al., “HER2 testing in gastric cancer: a practical approach,” Modern Pathology, vol. 25, no. 5, pp. 637–650, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. H. Marx, L. Tharun, J. Muth et al., “HER-2 amplification is highly homogenous in gastric cancer,” Human Pathology, vol. 40, no. 6, pp. 769–777, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Bozzetti, F. V. Negri, C. A. Lagrasta et al., “Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma,” British Journal of Cancer, vol. 104, no. 9, pp. 1372–1376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Pagni, S. Zannella, S. Ronchi, C. Garanzini, and B. E. Leone, “HER2 status of gastric carcinoma and corresponding lymph node metastasis,” Pathology and Oncology Research, vol. 19, no. 1, pp. 103–109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Ikari, G. Nakajima, K. Taniguchi et al., “HER2-positive gastric cancer with paraaortic nodal metastasis successfully resected after chemotherapy with trastuzumab: a case report,” Anticancer research, vol. 34, no. 2, pp. 867–872, 2014. View at Google Scholar · View at Scopus
  28. H. Yoshida, N. Yamamoto, H. Taniguchi et al., “Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma,” Virchows Archiv, vol. 465, no. 2, pp. 145–154, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 3, 2014.
  30. H. Okabe, S. Ueda, K. Obama, H. Hosogi, and Y. Sakai, “Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination,” Annals of Surgical Oncology, vol. 16, no. 12, pp. 3227–3236, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Suzuki, K. Tanabe, J. Taomoto et al., “Preliminary trial of adjuvant surgery for advanced gastric cancer,” Oncology Letters, vol. 1, no. 4, pp. 743–747, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Kanda, K. Yajima, S.-I. Kosugi, T. Ishikawa, Y. Ajioka, and K. Hatakeyama, “Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study,” Gastric Cancer, vol. 15, no. 3, pp. 235–244, 2012. View at Publisher · View at Google Scholar · View at Scopus